BRPI0519626A2 - mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse - Google Patents

mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse

Info

Publication number
BRPI0519626A2
BRPI0519626A2 BRPI0519626-4A BRPI0519626A BRPI0519626A2 BR PI0519626 A2 BRPI0519626 A2 BR PI0519626A2 BR PI0519626 A BRPI0519626 A BR PI0519626A BR PI0519626 A2 BRPI0519626 A2 BR PI0519626A2
Authority
BR
Brazil
Prior art keywords
protein
content
contaminants
composition
cell culture
Prior art date
Application number
BRPI0519626-4A
Other languages
English (en)
Inventor
Anne Charlotte Arentsen
Daniel E Rasmussen
Are Bogsnes
Arne Staby
Haleh Ahmadian
Susanne Bang
Janus Krarup
Thomas Budde Hansen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0519626A2 publication Critical patent/BRPI0519626A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MÉTODOS PARA A REDUÇçO DO TEOR DE UM OU MAIS CONTAMINANTES, DO TEOR DE PROTEÍNA S EM UMA COMPOSIÇçO, DO TEOR DE UM OU MAIS CONTAMINANTES DE PROTEÍNA EM UM SOBRENADANTE DE CULTURA DE CÉLULA, DO TEOR DE PROTEÍNA 5 EM UM SOBRENADANTE DE CULTURA DE CÉLULA, COMPOSIÇçO COMPREENDENDO UMA PROTEÍNA DEPENDENTE DE VITAMINA K DE INTERESSE. A invenção refere-se a composições de proteína dependentes de vitamina K tendo um teor muito baixo, ou negligível, de contaminantes de proteína. A presente invenção também se refere a método aplicável na preparação de tais composições de proteínas dependentes de vitamina K. Tais métodos poderão ser utilizados sozinhos ou em combinação seqúencial, com a finalidade de reduzir o teor relativo de contaminantes de proteína. A presente invenção é especialmente relevante na preparação de composições de fatores de coagulação escolhidos de polipeptídeos do fator X (FX/FXa), polipeptídeos do fator IX (FIX/FIXa), polipeptídeos do fator VII (FVII/FVIIa) e a proteína C anticoagulante, especialmente os polipeptideos do fator VII.
BRPI0519626-4A 2004-12-23 2005-12-23 mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse BRPI0519626A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200402008 2004-12-23
PCT/EP2005/057145 WO2006067230A1 (en) 2004-12-23 2005-12-23 Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest

Publications (1)

Publication Number Publication Date
BRPI0519626A2 true BRPI0519626A2 (pt) 2009-02-25

Family

ID=36168465

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519626-4A BRPI0519626A2 (pt) 2004-12-23 2005-12-23 mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse

Country Status (13)

Country Link
US (1) US9187549B2 (pt)
EP (2) EP2360171A1 (pt)
JP (2) JP2008525381A (pt)
KR (2) KR20130128013A (pt)
CN (1) CN101098883B (pt)
AU (1) AU2005318106B2 (pt)
BR (1) BRPI0519626A2 (pt)
CA (1) CA2592054A1 (pt)
ES (1) ES2395544T3 (pt)
MX (1) MX2007007356A (pt)
PL (1) PL1831242T3 (pt)
RU (1) RU2460735C2 (pt)
WO (1) WO2006067230A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
WO2007006808A1 (en) * 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
AT502691A1 (de) * 2005-10-24 2007-05-15 Univ Fuer Weiterbildung Krems Extrakorporales blut- oder plasmareinigungssystem
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
CN101730707B (zh) * 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
KR101821143B1 (ko) * 2008-12-02 2018-01-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드 정제
FR2946348B1 (fr) * 2009-06-05 2011-08-05 Lab Francais Du Fractionnement Procede de preparation d'une composition de complexe prothrombique a haut degre de purete
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2011073235A1 (en) 2009-12-18 2011-06-23 Csl Ltd. Method of purifying polypeptides
BR112012017696A2 (pt) 2010-01-18 2017-10-03 Novo Nordisk Healthcare Ag Purificação de fatores de coagulação de sangue
WO2011121020A1 (en) * 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
SG185005A1 (en) 2010-04-29 2012-11-29 Baxter Int Purification method for divalent cation binding proteins on anion exchange resin
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
CN102161701A (zh) * 2011-01-28 2011-08-24 上海兴迪金生物技术有限公司 从细胞培养液或血浆组分中分离纯化高纯度活化凝血七因子的方法
JP2011172602A (ja) * 2011-06-15 2011-09-08 Jcr Pharmaceuticals Co Ltd 組換え体ヒトｆｓｈの製造方法
ES2700933T3 (es) * 2011-10-14 2019-02-20 Baxalta GmbH Purificación de proteínas mediante cromatografía de intercambio aniónico
AU2012322948B2 (en) * 2011-10-14 2014-11-06 Takeda Pharmaceutical Company Limited Protein purification by anion exchange chromatography
NZ629845A (en) 2013-03-15 2016-10-28 Baxalta Inc Purification method for vitamin k dependent proteins by anion exchange chromatography
DE112014002349B4 (de) 2013-05-10 2019-12-05 Denso Corporation Kraftstoffeinspritzsteuervorrichtung und Kraftstoffeinspritzsystem
JP5750471B2 (ja) * 2013-05-22 2015-07-22 Ｊｃｒファーマ株式会社 組換え体ヒトｆｓｈの製造方法
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
JP7030834B2 (ja) 2017-03-16 2022-03-07 深▲セン▼先進技術研究院 エネルギー代謝を調節するポリペプチド及びその使用
WO2018165933A1 (zh) * 2017-03-16 2018-09-20 深圳先进技术研究院 调节糖代谢的多肽及其用途
EP3590528A1 (en) * 2018-07-06 2020-01-08 Octapharma AG Fx activation process and its use in the preparation of a fxa composition
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
EP0118256B1 (en) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbent, and method of recovering vitamin-k dependent protein therewith
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
JPH0759600B2 (ja) 1986-12-15 1995-06-28 帝人株式会社 ヒト・プロテインｓに対するモノクローナル抗体
JPH01231893A (ja) 1988-03-14 1989-09-18 Fuji Yakuhin Kogyo Kk 抗ヒトプロテインｓモノクローナル抗体およびその利用
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
CA2143125C (en) * 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE4406515C1 (de) 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
US6117996A (en) 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
JP3745805B2 (ja) * 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
WO1997040145A1 (en) 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP2000143692A (ja) 1998-11-11 2000-05-26 Fujimori Kogyo Co Ltd モノクローナル抗体によって精製されたトロンビン基質または阻害剤の精製方法
EP2348044A1 (en) 1999-03-15 2011-07-27 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
EP1198565A1 (en) 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
JP2001247599A (ja) 2000-03-07 2001-09-11 Fujimori Kogyo Co Ltd ポリペプチド、それを用いた血液凝固因子吸着体、該吸着体を用いた血液凝固因子の精製方法、および該ポリペプチドを含有する血栓形成予防剤
US6952212B2 (en) 2000-03-24 2005-10-04 Telefonaktiebolaget Lm Ericsson (Publ) Frame decimation for structure from motion
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
BR0114373A (pt) * 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
RU2321633C2 (ru) * 2001-02-16 2008-04-10 Ново Нордиск Хелт Кэр Аг Способ получения витамин к-зависимых белков
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
EP1434857B1 (en) 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Method for production of recombinant proteins in eukaryote cells
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
WO2003093465A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
CA2484173A1 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
JP4597678B2 (ja) 2002-09-25 2010-12-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉポリペプチド
CA2840692A1 (en) 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest

Also Published As

Publication number Publication date
JP2008525381A (ja) 2008-07-17
PL1831242T3 (pl) 2013-04-30
RU2460735C2 (ru) 2012-09-10
EP2360171A1 (en) 2011-08-24
ES2395544T3 (es) 2013-02-13
EP1831242B1 (en) 2012-09-26
JP5866274B2 (ja) 2016-02-17
CN101098883A (zh) 2008-01-02
US9187549B2 (en) 2015-11-17
CA2592054A1 (en) 2006-06-29
JP2013100300A (ja) 2013-05-23
CN101098883B (zh) 2013-01-23
KR101364001B1 (ko) 2014-02-17
US20080207880A1 (en) 2008-08-28
KR20070100732A (ko) 2007-10-11
MX2007007356A (es) 2007-08-14
RU2007122413A (ru) 2009-01-27
EP1831242A1 (en) 2007-09-12
WO2006067230A1 (en) 2006-06-29
KR20130128013A (ko) 2013-11-25
AU2005318106B2 (en) 2011-11-03
AU2005318106A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
BRPI0519626A2 (pt) mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse
Castiblanco et al. Identification of proteins from human permanent erupted enamel
Hrženjak et al. Fibrinolytic and anticoagulative activities from the earthworm Eisenia foetida
Rajesh et al. Procoagulant activity of Calotropis gigantea latex associated with fibrin (ogen) olytic activity
Seneci et al. A clot twist: Extreme variation in coagulotoxicity mechanisms in Mexican neotropical rattlesnake venoms
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
IL217489A (en) U-pa polypeptides with specific substrate activity or activity and preparations and uses based on these polypeptides
FR2969142B1 (fr) Methode de cimentation a temperature ambiante de cendres volantes a faible teneur en calcium
Patiño et al. Isolation and biological characterization of Batx-I, a weak hemorrhagic and fibrinogenolytic PI metalloproteinase from Colombian Bothrops atrox venom
BRPI0711767B8 (pt) composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
NO20064584L (no) Tetrahydropyridoindolderivater
Varadi et al. Pro‐and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy
NO20074278L (no) Tigecyklinblandinger og fremgangsmater for fremstilling
BRPI0507856A (pt) composição farmacêutica, e, processo para preparar o anticorpo abeta
ATE534290T1 (de) Apparat zur verlängerung der überlebensdauer von blutplättchen
WO2008092644A3 (en) Fviii-independent fix-mutant proteins for hemophilia a treatment
Rastogi et al. Partial purification and identification of a metalloproteinase with anticoagulant activity from Rhizostoma pulmo (Barrel Jellyfish)
DE60134280D1 (de) In vitro rekonstituierte lagen des menschlichen ho
Stanley et al. Amino acids responsible for reduced affinities of vitamin K-dependent propeptides for the carboxylase
Chen et al. New insights into the functions and N‐glycan structures of factor X activator from Russell’s viper venom
Torres-Huaco et al. Rapid Purification and Procoagulant and Platelet Aggregating Activities of Rhombeobin: A Thrombin‐Like/Gyroxin‐Like Enzyme from Lachesis muta rhombeata Snake Venom
DK1922128T3 (da) Element til reduktion af indholdet af finstøv i luften ved anvendelse af mos og/eller lav

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO SOLICITADA ATRAVES DA PETICAO NO 870180131039 DE 17/09/2018.